Pharmasset, Inc. (VRUS) news stock charts
Pharmasset, Inc. (VRUS) Investment Summary:
We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency virus, or HIV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication. We are currently focusing on three product candidates, two of which we are developing ourselves and one of which we are developing with a strategic partner: • Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America (“the Americas”) and Europe; • R7128, a pro-drug of PSI-6130 for the treatment of HCV, in Part 3 ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f12%2f31%2f0001193125-07-273372.html#FIS_BUSINESS"www.pharmasset.com
65 Employees
Founded in 1998
PHARMASSET INC (VRUS:NASDAQ)
LAST $29.07 USD
CHANGE TODAY +0.06 0.21%
VOLUME 731.2K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of PHARMASSET INC (VRUS)
|
OPEN
$28.96
|
PREVIOUS CLOSE
$29.01
|
|
|
DAY HIGH
$29.18
|
DAY LOW
$28.42
|
|
|
52 WEEK HIGH
03/18/10 - $29.50
|
52 WEEK LOW
04/20/09 - $7.69
|
|
|
MARKET CAP
876.6M
|
AVERAGE VOLUME 10 D
267.5K
|
|
|
EPS TTM
$-1.86
|
SHARES OUTSTANDING
30.2M
|
|
|
VRUS Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for PHARMASSET INC (VRUS)
Pharmasset, Inc. Announces Complete Enrollment of RG7128 Phase 2b Clinical Study
02/17/2010
Pharmasset, Inc. announced the complete enrollment by Roche of the 12 week RG7128 Phase 2b study (PROPEL) of approximately 400 treatment-naive patients with hepatitis C virus (HCV) genotypes 1 and 4. The study remains blinded to Roche and Pharmasset. Roche has initiated a 24 week Phase 2b study with RG7128 in combination with pegylated interferon and ribavirin in treatment-naive patients with HCV genotypes 1 and 4 in order to evaluate the safety and efficacy of RG7128 in combination with standard of care for longer durations. The data from this study could provide the flexibility for combining RG7128 with direct acting antivirals currently in development with varying durations of therapy. This study is currently enrolling at sites in the US and Canada and is expected to complete enrollment in the second quarter. In addition, Roche is planning to initiate a Phase 2b study of RG7128 in combination with pegylated interferon and ribavirin in patients with HCV genotypes 2 and 3 later in 2010. RG7128 has previously demonstrated antiviral activity with a 90% RVR in HCV genotypes 2 and 3 prior non-responders in a 28 day clinical study. Roche has also announced that it will not conduct the previously planned 28 day INFORM-2 study, designed to evaluate the combination of RG7128 with RG7227, InterMune's HCV protease inhibitor, with and without pegylated interferon and ribavirin. Roche has decided instead to conduct longer duration studies, including the INFORM-3 clinical study of RG7128 and RG7227 with and without pegylated interferon and ribavirin. INFORM-3 will commence after Roche and InterMune identify the optimal dose of ritonavir-boosted RG7227 from ongoing studies. Roche is continuing to conduct dose ranging safety and efficacy studies of RG7227, and has announced a consequent delay of the INFORM-3 clinical study.
Pharmasset, Inc. expected to Report Q2 2010 Results on April 30, 2010. This event was calculated by Capital IQ (Created on February 10, 2010).
02/10/2010
Pharmasset, Inc. expected to Report Q2 2010 Results on April 30, 2010. This event was calculated by Capital IQ (Created on February 10, 2010).
Pharmasset, Inc. Reports Unaudited Financial Results for the First Quarter Ended December 31, 2009
02/9/2010
Pharmasset, Inc. reported unaudited financial results for the first quarter ended December 31, 2009. For the quarter, the company reported revenues of $0.3 million compared to $0.5 million for the quarter ended December 31, 2008 and reflect the amortization of up front and subsequent collaborative and license payments received from Roche. Net cash used in operating activities was $14.5 million as compared to $15.3 million for the quarter ended December 31, 2008. The company reported net loss of $13.9 million, or $0.49 per share as compared to a net loss of $18.3 million, or $0.78 per share, for the quarter ended December 31, 2008. Operating loss was $13.2 million against $17.6 million a year ago. Loss before income taxes was $13.9 million against $18.3 million a year ago.
Pharmasset, Inc. financial resources
VRUS Competitors
| Company | Last | Change |
| Idenix Pharmaceuticals Inc | $2.81 USD | -0.08 |
| Medivir AB | kr128.75 SEK | -2.25 |
| Orexigen Therapeutics Inc | $6.07 USD | +0.01 |
| Targacept Inc | $19.23 USD | +0.54 |
| Vanda Pharmaceuticals Inc | $11.76 USD | -0.06 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | VRUS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 62.8x |
|
| Price/Book | 48.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 62.3x |
|
|
VRUS |
||
|
VRUS transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Pharmasset, Inc.
PHARMASSET INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
2010-02-22 06:17:47
Quote: Other Events.
On February 17, 2010, Pharmasset, Inc. (the "Company") issued a press release
announcing the complete enrollment by Roche of a Phase 2b clinical study of
RG7128, a prodrug of PSI-6130 that the Company is developing with Roche, for the
treatment of chronic hepatitis C (HCV). The Company also announced that Roche
will not conduct the previously planned 28 day INFORM-2 study, designed to
evaluate the combination of RG7128 with RG7227, InterMune, Inc.'s protease
inhibitor, w...Read article
Pharmasset Prices Underwritten Offering of Common Stock
2010-02-17 05:20:24
Quote: 28 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the pricing of an underwritten offering of 1,600,000 shares of its common stock at a price of $18.75. After the underwriting discount and estimated offering expenses, Pharmasset expects to receive net proceeds of approximately $28.6 million. In addition, Pharmasset has granted the underwriter a 30-day option to purchase up to an additional 230,400 shares of its common stock. The offering is expected to close on February...Read article
Pharmasset Announces Proposed Public Offering of Common Stock
2010-02-17 05:20:24
Quote: 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that it has commenced an underwritten public offering, subject to market and other conditions, of $30,000,000 of its common stock pursuant to effective shelf registration statements. Pharmasset intends to grant to the underwriters a 30-day option to purchase up to an additional $4,000,000 of common stock. Leerink Swann LLC is acting as sole book-running manager for the offering. Pharmasset intends to use the net proceed...Read article
Pharmasset Reports Fiscal First Quarter 2010 Financial Results
2010-02-17 05:20:23
Quote: 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal quarter ended December 31, 2009. Financial ResultsRevenues were $0.3 million during the quarter ended December 31, 2009 compared to $0.5 million for the quarter ended December 31, 2008 and reflect the amortization of up-front a...Read article
Pharmasset Announces Exercise of Underwriter's Option
2010-02-17 05:20:23
Quote: 29 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the underwriter of its recent stock offering has exercised its option to purchase an additional 230,400 shares of common stock. The net proceeds to Pharmasset, Inc., after deducting the underwriting discount, from the sale of these additional shares are expected to be approximately $4.1 million. This brings the total expected proceeds of the offering, after deducting the underwriting discount and estimated offering expe...Read article
Pharmasset Reports Fiscal First Quarter 2010 Financial Results
2010-02-10 04:47:09
Quote: 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal quarter ended December 31, 2009. Financial ResultsRevenues were $0.3 million during the quarter ended December 31, 2009 compared to $0.5 million for the quarter ended December 31, 2008 and reflect the amortization of up-front a...Read article
Pharmasset Announces Exercise of Underwriter's Option
2010-02-01 02:43:32
Quote: 29 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the underwriter of its recent stock offering has exercised its option to purchase an additional 230,400 shares of common stock. The net proceeds to Pharmasset, Inc., after deducting the underwriting discount, from the sale of these additional shares are expected to be approximately $4.1 million. This brings the total expected proceeds of the offering, after deducting the underwriting discount and estimated offering expe...Read article
Pharmasset Prices Underwritten Offering of Common Stock
2010-01-29 02:46:24
Quote: 28 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the pricing of an underwritten offering of 1,600,000 shares of its common stock at a price of $18.75. After the underwriting discount and estimated offering expenses, Pharmasset expects to receive net proceeds of approximately $28.6 million. In addition, Pharmasset has granted the underwriter a 30-day option to purchase up to an additional 230,400 shares of its common stock. The offering is expected to close on February...Read article
PHARMASSET INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
2010-01-29 02:46:23
Quote: Entry Into a Material Definitive Agreement.
On January 27, 2010, Pharmasset, Inc. (the "Company") entered into an
underwriting agreement (the "Underwriting Agreement") with Leerink Swann LLC
(the "Underwriter") relating to an underwritten public offering (the "Offering")
of 1,600,000 shares of the Company's common stock, par value $0.001 per share
(the "Common Stock"), and an additional 230,400 shares of Common Stock for which
the Underwriter ...Read article
Pharmasset Announces Proposed Public Offering of Common Stock
2010-01-28 01:48:36
Quote: 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that it has commenced an underwritten public offering, subject to market and other conditions, of $30,000,000 of its common stock pursuant to effective shelf registration statements. Pharmasset intends to grant to the underwriters a 30-day option to purchase up to an additional $4,000,000 of common stock. Leerink Swann LLC is acting as sole book-running manager for the offering. Pharmasset intends to use the net proceed...Read article
PHARMASSET INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
2010-01-26 02:34:02
Quote: Other Events.
On January 21, 2010, Pharmasset, Inc. (the "Company") issued a press release
announcing the initiation of a 28-day Phase 2a study of PSI-7977, a chirally
pure isomer form of PSI-7851, a nucleotide analog polymerase inhibitor in
development for the treatment of chronic hepatitis C (HCV). The trial will
evaluate various doses of PSI-7977 in combination with Pegasys (peginterferon
alfa 2a) and Copegus (ribavirin) in patients with HCV genotype 1 who have not
been treated pre...Read article
Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851
2010-01-22 02:13:59
Quote: 21 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announces the initiation of a 28-day Phase 2a study with PSI-7977, a chirally pure isomer form of PSI-7851, a nucleotide analog polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV). The trial will evaluate various doses of PSI-7977 in combination with Pegasys (peginterferon alfa 2a) and Copegus (ribavirin) in patients with HCV genotype 1 who have not been treated previously. "We recently reported enc...Read article
Pharmasset: hepatitis C drug trial will continue
2010-01-19 03:21:13
Quote: The committee found that side effects, discontinuations, and other events were similar in both groups.Pharmasset, of Princeton, N.J., said its partner Roche of Switzerland will open enrollment for the remaining 300 subjects.The review was based on eight or 12 weeks of treatment. Pharmasset said Roche is going to start several longer studies in the first half of 2010. Pharmasset said Roche will begin a separate study of RG7128 in subjects with different strains of hepatitis C.In afternoon trading...Read article
Pharmasset Reports Fiscal Year End 2009 Financial Results
2010-01-19 03:21:12
Quote: The study investigated the combination of Pharmasset's RG7128 with InterMune's RG7227, an HCV protease inhibitor.In April 2009, Pharmasset, Roche and InterMune reported interim results from this study at the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. These interim results demonstrated for the first time that the combination of an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV viral load reduction in patients wit...Read article
Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
2010-01-19 03:21:10
Quote: 8 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the 28th Annual JPMorgan Healthcare Conference being held from January 11 to 14, 2010 at the Westin St Francis in San Francisco, CA. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company at the conference on Thursday, January 14, 2010 at 2:00 PM (PT).http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minute...Read article
Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
2010-01-11 04:08:43
Quote: 8 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the 28th Annual JPMorgan Healthcare Conference being held from January 11 to 14, 2010 at the Westin St Francis in San Francisco, CA. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company at the conference on Thursday, January 14, 2010 at 2:00 PM (PT).http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minute...Read article
PHARMASSET INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
2009-12-02 03:48:44
Quote: Results of Operations and Financial Condition.
On November 25, 2009, Pharmasset, Inc. (the "Company") issued a press release
announcing financial results for the fiscal year ended September 30, 2009. The
full text of the press release issued in connection with the announcement is
attached hereto as Exhibit 99.1 and is incorporated by reference.
The information in this Current Report on Form 8-K, including the exhibit
attached hereto, is furnished pursuant to Item 2.02 of Form 8-K and ...Read article
INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
2009-11-30 04:45:09
Quote: 3 /PRNewswire-FirstCall/ --ITMNNewsVRUSNews) today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1 study of two direct-acting antiviral (DAA) compounds administered without interferon or ribavirin for the treatment of patients chronically infected with the hepatitis C virus (HCV).(i)The study, conducted by Roche as part of its collaborations with InterMune and Pharmasset, combined the oral NS3 protease inhibitor RG7227 (also known as ITMN-191) and the oral...Read article
Pharmasset Reports Fiscal Year End 2009 Financial Results
2009-11-30 04:45:07
Quote: The study investigated the combination of Pharmasset's RG7128 with InterMune's RG7227, an HCV protease inhibitor.In April 2009, Pharmasset, Roche and InterMune reported interim results from this study at the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. These interim results demonstrated for the first time that the combination of an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV viral load reduction in patients wit...Read article
Pharmasset: hepatitis C drug trial will continue
2009-11-30 04:45:07
Quote: The committee found that side effects, discontinuations, and other events were similar in both groups.Pharmasset, of Princeton, N.J., said its partner Roche of Switzerland will open enrollment for the remaining 300 subjects.The review was based on eight or 12 weeks of treatment. Pharmasset said Roche is going to start several longer studies in the first half of 2010. Pharmasset said Roche will begin a separate study of RG7128 in subjects with different strains of hepatitis C.In afternoon trading...Read article
Would you like to leave a comment about Pharmasset, Inc. VRUS
Find out what social network information about Pharmasset, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Pharmasset, Inc.'s Stock there is more great penny stock and market information at Realpennies